BusinessGeneTx Biotherapeutics receives FDA orphan-drug designation for Angelman syndrome treatmentBy Nasdaq OMXMar 27, 2018, 5:26 PM UTC
BusinessNew biotech launched for antisense program targeting Angelman syndromeBy Nasdaq OMXFeb 22, 2018, 2:11 PM UTC
